Search

Changes to Formulary as of 6th April 2018:

BNF Category Number

Product/indication

Detail of change

8.2.4

Atezolizumab

Added as a RED drug and added link to NICE TA492

8.1.3

Cladribine

Added link to NICE TA493

4.5.1

Naltrexone-bupropion

Added as a NOT APPROVED drug and added link to NICE TA494

8.1.5

Palbociclib

Added as a RED drug and added link to NICE TA495

8.1.5

Ribococlib

Added as a RED drug and added link to NICE TA496

10.1.3

Golimumab

Added link to NICE TA497

8.1.5

Lenvatinib

Added as a RED drug and added link to NICE TA498

5.3.3.2

Glecaprevir-pibrentasvir

Added as a RED drug and added link to NICE TA499

8.1.5

Ceritinib

Added link to NICE TA500

8.1.5

Ibrutinib

Added link to NICE TA502

8.3.4.1

Fulvestrant

Added as a NOT APPROVED drug and added link to NICE TA503

10.3.2

PR Freeze Spray

Removed from Chapter 10 of formulary. Should only be used to test effect of local anaesthetic

12.3.5

Biotene and Bioxantra

Changed to GREEN

11.4.2

Sodium Cromoglycate 2% eye drops

Remove from formulary

8.1.5

Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected

Added link to MHRA DSU guidance

8.1.5

Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures

Added link to MHRA DSU guidance

1.4.2

Eluxadoline (Truberzi▼): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders

Added link to MHRA DSU guidance

8.2.4

Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk

Added link to MHRA DSU guidance

8.2.4

Fingolimod (Gilenya▼): updated advice about risk of cancers and serious infections

Added link to MHRA DSU guidance

8.2.4

Daclizumab (Zinbryta▼) and risk of severe liver injury: new restrictions to use and strengthened liver monitoring

Added link to MHRA DSU guidance

9.1.3a

Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

Added link to MHRA DSU guidance